- Shares of Synta Pharmaceuticals (SNTA -6.3%) are notably lower on the session.
- Highlights from the company's Q3 report include: Final OS results from GALAXY-1 by "early 2014;" interim and final analyses of GALAXY-2 in H2 2014 and H1 2015, respectively; ENCHANT-1 initial results at the San Antonio Breast Cancer Symposium in December; cash position at quarter's end was $53.4M (versus $100.6M as of December 31, 2012), enough to last "into Q2 2014." (PR)
- According to market chatter, Roth Capital thinks the company could have a partnership "up its sleeve."
From other sites
at Zacks.com (Mar 12, 2015)
at Zacks.com (Mar 11, 2015)
at Zacks.com (Mar 6, 2015)
at CNBC.com (Jan 10, 2014)
at CNBC.com (Oct 16, 2013)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs